XML 30 R16.htm IDEA: XBRL DOCUMENT
v3.21.1

10. SHAREHOLDERS' EQUITY | 3 Months Ended
--- | ---
Mar. 31, 2021
Stockholders' Equity: |
SHAREHOLDERS' EQUITY | Our Board of Directors (the “Board”) may, without further action by our shareholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up by us before any payment is made to the holders of our common stock. Furthermore, the Board could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock. Reverse Stock Split On September 9, 2020, the Board approved a reverse stock split of our common stock and our Convertible Series A Preferred Stock, in each case, at a ratio of 1-for-8 and without any change to the respective par value thereof (the “Reverse Stock Split”), and, on September 10, 2020, we filed an Articles of Amendment to our Articles of Incorporation with the Department of State of the State of Florida to effect the Reverse Stock Split. The Reverse Stock Split became effective as of September 10, 2020 (the “Effective Time”). All per-share and share amounts have been retroactively restated in this Quarterly Report on Form 10-Q for all periods presented to reflect the reverse stock split. Convertible Series A Preferred Stock Our authorized Convertible Series A Preferred Stock, $0.01 par value, consists of 1,000,000 shares. At March 31, 2021 and December 31, 2020, there were 63,750 shares issued and outstanding. The Convertible Series A Preferred Stock is convertible at the rate of one share of common stock for one share of Convertible Series A Preferred Stock. Convertible Series B Preferred Stock Our authorized Convertible Series B Preferred Stock, $1,000 stated value, 7.5% cumulative dividend, consists of 4,000 shares. At March 31, 2021 and December 31, 2020, there were no shares issued and outstanding, respectively. Each share of Convertible Series B Preferred Stock may be converted (at the holder’s election) into two hundred shares of our common stock. Common Stock During the three months ended March 31, 2020, we issued 50,000 shares of fully vested common stock valued at $48,000 to members of our Board (see Note 12). In March 2020, 1,041,667 shares of common stock were issued in connection with the conversion of convertible notes payable aggregating $4,500,000. In March 2020, 10,417 shares of common stock were issued in connection with the exercise of warrants for which we received proceeds of $57,500. During the three months ended March 31, 2021, we issued 50,000 shares of common stock valued at $228,000 to members of our Board (see Note 12). Stock Options There were no options granted during the first quarter of 2021. In January 2020 we issued two options to purchase an aggregate of 31,250 shares of common stock to our Chief Operating Officer at an exercise price of $0.80 and $0.96 per share pursuant to her employment agreement with us. The options were valued at a total of $23,595 and have a term of 5 years. We utilized the Black-Scholes method to fair value the options received by the COO with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the options was $0.72 and $0.80. The value of the stock option was included in accrued expenses at December 31, 2019. The following table summarizes stock options outstanding as of March 31, 2021 and December 31, 2020:
|  | March 31, 2021 |  |  |  |
|  | (Unaudited) |  |  | December 31, 2020 |
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Number of Options |  |  | Weighted Average Exercise Price |
Outstanding, beginning of period |  |  | 132,500 |  |  | $ | 2.72 |  |  |  | 77,500 |  |  | $ | 2.56 |
Granted |  |  | - |  |  |  | - |  |  |  | 62,500 |  |  |  | 3.96 |
Exercised |  |  | - |  |  |  | - |  |  |  | (2,500 | ) |  |  | 0.40 |
Expired |  |  | - |  |  |  | - |  |  |  | (5,000 | ) |  |  | 16.80 |
Outstanding, end of period |  |  | 132,500 |  |  | $ | 2.72 |  |  |  | 132,500 |  |  | $ | 2.72 |
Options outstanding and exercisable by price range as of March 31, 2021 were as follows:
| Outstanding Options |  |  | Average Weighted |  |  | Exercisable Options |
| Range |  |  | Number |  |  | Remaining Contractual Life in Years |  |  | Number |  |  | Weighted Average Exercise Price |
| $ | 0.80 |  |  |  | 27,500 |  |  |  | 3.85 |  |  |  | 27,500 |  |  | $ | 0.80 |
| $ | 0.88 |  |  |  | 31,250 |  |  |  | 2.76 |  |  |  | 31,250 |  |  | $ | 0.88 |
| $ | 0.96 |  |  |  | 25,000 |  |  |  | 2.77 |  |  |  | 25,000 |  |  | $ | 0.96 |
| $ | 2.16 |  |  |  | 5,000 |  |  |  | 3.76 |  |  |  | 5,000 |  |  | $ | 2.16 |
| $ | 4.40 |  |  |  | 12,500 |  |  |  | 4.85 |  |  |  | 12,500 |  |  | $ | 4.40 |
| $ | 7.06 |  |  |  | 31,250 |  |  |  | 4.50 |  |  |  | 31,250 |  |  | $ | 7.06 |
|  |  |  |  |  | 132,500 |  |  |  | 3.64 |  |  |  | 132,500 |  |  | $ | 2.72 |
Stock Warrants In January 2020 we issued a warrant to purchase 156,250 shares of common stock to our Chief Executive Officer at an exercise price of $1.20 per share pursuant to an employment agreement. The warrant was valued at $164,201 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by our Chief Executive Officer with the following assumptions: volatility, 136%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $1.04. In January 2020 we issued a warrant to purchase 5,208 shares of common stock to an employee at an exercise price of $0.96 per share. The warrant was valued at $3,594 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.58%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $0.72. The value of the warrants was expensed in the fourth quarter of 2019 and included in accrued expenses at December 31, 2019. In February 2020 we issued a warrant to purchase 18,750 shares of common stock to an employee at an exercise price of $1.20 per share. The warrant was valued at $18,571 and has a term of 3 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 155%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 3 years. The grant date fair value of each share of common stock underlying the warrant was $0.96. On February 11, 2021, we agreed to amend (the “Warrant Amendment”) the warrant to purchase 125,000 shares of TOMI common stock, par value $0.01 (the “Common Stock”), issued by TOMI to Dr. Halden S. Shane, TOMI’s Chief Executive Officer and a director on TOMI’s board of directors, on February 11, 2014 (the “Warrant”), to provide TOMI an option to repurchase the Warrant from Dr. Shane at a negotiated price. In connection with the Warrant Amendment, TOMI repurchased the warrant from Dr. Shane (the “Repurchase”) for an aggregate cash consideration of $314,500, representing a 15% discount of the net exercise cash value of the Warrant, which was calculated using the closing price of the Common Stock on the Nasdaq on February 11, 2021 of $5.36, less the exercise price of the warrants in the amount of $2.40. On the same date, the Warrant Amendment and the Repurchase was considered, approved and adopted by a disinterested majority of TOMI’s board of directors. The $314,500 charge in connection with the warrant amendment has been included in General and Administrative expenses for the three months ended March 31, 2021. The following table summarizes the outstanding common stock warrants as of March 31, 2021 and December 31, 2020:
|  | March 31, 2021 (Unaudited) |  |  | December 31, 2020 |
|  | Number of Warrants |  |  | Weighted Average Exercise Price |  |  | Number of Warrants |  |  | Weighted Average Exercise Price |
Outstanding, beginning of period |  |  | 2,049,133 |  |  | $ | 2.55 |  |  |  | 2,155,065 |  |  | $ | 3.12 |
Granted |  |  | - |  |  |  | - |  |  |  | 585,447 |  |  |  | 4.97 |
Exercised |  |  | - |  |  |  | - |  |  |  | (76,796 | ) |  |  | (2.77 | )
Expired |  |  | (168,750 | ) |  |  | (2.84 | ) |  |  | (614,583 | ) |  |  | (6.40 | )
Outstanding, end of period |  |  | 1,880,383 |  |  | $ | 2.66 |  |  |  | 2,049,133 |  |  | $ | 2.55 |
Warrants outstanding and exercisable by price range as of March 31, 2021 were as follows:
| Outstanding Warrants |  |  |  |  |  | Exercisable Warrants |
| Exercise Price |  |  | Number |  |  | Average Weighted Remaining Contractual Life in Years |  |  | Number |  |  | Weighted Average Exercise Price |
| $ | 0.64 |  |  |  | 31,250 |  |  |  | 2.65 |  |  |  | 31,250 |  |  | $ | 0.64 |
| $ | 0.80 |  |  |  | 158,125 |  |  |  | 2.51 |  |  |  | 158,125 |  |  | $ | 0.80 |
| $ | 0.96 |  |  |  | 473,958 |  |  |  | 1.69 |  |  |  | 473,958 |  |  | $ | 0.96 |
| $ | 1.12 |  |  |  | 6,250 |  |  |  | 3.05 |  |  |  | 6,250 |  |  | $ | 1.12 |
| $ | 1.20 |  |  |  | 175,000 |  |  |  | 3.63 |  |  |  | 175,000 |  |  | $ | 1.20 |
| $ | 1.36 |  |  |  | 1,250 |  |  |  | 1.57 |  |  |  | 1,250 |  |  | $ | 1.36 |
| $ | 2.16 |  |  |  | 31,250 |  |  |  | 0.75 |  |  |  | 31,250 |  |  | $ | 2.16 |
| $ | 2.32 |  |  |  | 523,061 |  |  |  | 0.91 |  |  |  | 523,061 |  |  | $ | 2.32 |
| $ | 2.40 |  |  |  | 12,500 |  |  |  | 0.50 |  |  |  | 12,500 |  |  | $ | 2.40 |
| $ | 2.56 |  |  |  | 31,250 |  |  |  | 0.50 |  |  |  | 31,250 |  |  | $ | 2.56 |
| $ | 3.36 |  |  |  | 31,250 |  |  |  | 0.25 |  |  |  | 31,250 |  |  | $ | 3.36 |
| $ | 4.00 |  |  |  | 28,750 |  |  |  | 4.35 |  |  |  | 28,750 |  |  | $ | 4.00 |
| $ | 6.95 |  |  |  | 375,000 |  |  |  | 9.50 |  |  |  | 375,000 |  |  | $ | 6.95 |
| $ | 8.40 |  |  |  | 1,488 |  |  |  | 2.38 |  |  |  | 1,488 |  |  | $ | 8.40 |
|  |  |  |  |  | 1,880,383 |  |  |  | 3.35 |  |  |  | 1,880,383 |  |  | $ | 2.66 |
There were no unvested warrants outstanding as of March 31, 2021.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration